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Abstract
Background: In humans, the presence of antiphospholipid antibodies (aPL) is frequently found in immune
thrombocytopenia. The present study investigated whether aPL and any aPL subtypes are associated with canine
thrombocytopenia, in particular, immune-mediated thrombocytopenia (immune thrombocytopenia) that usually
manifests with severe thrombocytopenia.
Results: Sera were collected from 64 outpatient dogs with thrombocytopenia (Group I, platelet count 0 – 80 ×
103/uL), and 38 of which having severe thrombocytopenia (platelet count < 30 × 103/uL) were further divided into
subgroups based on the presence of positive antiplatelet antibodies (aPLT) (subgroup IA, immune thrombocytopenia,
n =20) or the absence of aPLT (subgroup IB, severe thrombocytopenia negative for aPLT, n =18). In addition, sera of 30
outpatient dogs without thrombocytopenia (Group II), and 80 healthy dogs (Group III) were analyzed for comparison.
Indirect ELISAs were performed to compare serum levels of aPL subtypes, including anticardiolipin antibodies (aCL),
antiphosphatidylserine antibodies (aPS), antiphosphatidylcholine (aPC), and anti-β2 glycoprotein I antibodies (aβ2GPI),
and antiphosphatidylinositol antibodies (aPI), among different groups or subgroups of dogs. Among outpatient dogs,
aCL, being highly prevalent in outpatient dogs with thrombocytopenia (63/64, 98 %), is an important risk factor
for thrombocytopenia (with a high relative risk of 8.3), immune thrombocytopenia (relative risk 5.3), or severe
thrombocytopenia negative for aPLT (relative risk ∞, odds ratio 19). In addition, aPS is a risk factor for immune
thrombocytopenia or severe thrombocytopenia negative for aPLT (moderate relative risks around 2), whereas aPC
and aβ2GPI are risk factors for immune thrombocytopenia (relative risks around 2).
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Conclusions: Of all the aPL subtypes tested here, aCL is highly associated with canine thrombocytopenia, including
immune thrombocytopenia, severe thrombocytopenia negative for aPLT, and less severe thrombocytopenia.
Furthermore, aPS is moderately associated with both canine immune thrombocytopenia and severe thrombocytopenia
negative for aPLT, whereas aβ2GPI, and aPC are moderately relevant to canine immune thrombocytopenia. In contrast,
aPI is not significantly associated with canine immune thrombocytopenia.
Keywords: Anticardiolipin antibodies, Antiphosphatidylserine antibodies, Anti-β2 glycoprotein I antibodies,
Antiphosphatidylcholine antibodies, Antiphospholipid antibodies, Immune thrombocytopenia, Antiplatelet antibodies
Background
In humans, the presence of antiphospholipid antibodies
(aPL) is a diagnostic criterion for the antiphospholipid
syndrome (APS), which manifests with thrombosis or re-
current fetal loss in women and is often accompanied
with thrombocytopenia [1, 2]. APS in the absence of
other related autoimmune diseases is referred to as pri-
mary APS. Besides being present in primary APS, the
aPL autoantibodies are often found in patients with
other autoimmune diseases, especially systemic lupus
erythematosus (SLE) and immune thrombocytopenia
(immune-mediated thrombocytopenia) [1, 3]. The aPL
autoantibodies in humans have been recognized as lupus
anticoagulants (LA), anticardiolipin (aCL), antiphospha-
tidylinositol (aPI), antiphosphatidylserine (aPS), antipho-
sphatidic acid (aPA), antiphosphatidylglycine (aPG),
antiphosphatidylcholine (aPC), and anti-β2 glycoprotein
I antibodies (aβ2GPI) [4, 5]. Among them, aCL and
aβ2GPI detected by ELISA, together with LA determined
by screening assays, are now required as one or more of
the three laboratory criteria, along with one clinical
manifestation (either vascular thrombosis or recurrent
abortion in women), for the diagnosis of APS in humans
[2]. Alternatively, several reports have suggested that
APhL antibody ELISAs, which detect antibodies against
a mixture of noncardiolipin antigens (anti-noncardioli-
pin phospholipids antibodies, aPhL), can be used for hu-
man APS diagnosis [6–8]. Apart from thrombosis and
pregnancy morbidity, thrombocytopenia is a common
manifestation in both APS (20 to 53 %) [9] and SLE
patients (20 %) [10]. Although thrombocytopenia had
previously been proposed to serve as a preliminary clas-
sification criterion of APS in SLE patients [11], it was
not included in the later revised APS classification cri-
teria [2]. On the other hand, a recent investigation of 35
thrombocytopenia patients with aPL found that half of
them developed APS [12]. The authors of that study
suggested that aPL-positive thrombocytopenia patients,
along with less frequent hemolytic anemia patients,
should be considered as having hematologic APS [12].
Until now, canine aPL-related studies have been lim-
ited. In 2005, the presence of aCL was detected in 33 of
63 diseased dogs by setting a cut-off value based on the
sera of 134 healthy dogs, and four APS-like diseased
dogs, including one dog with recurrent abortion and se-
vere thrombocytopenia, were found to have high levels
of aCL [13]. Interestingly, 22 Bernese Mountain dogs, a
breed which has been shown to have a prolonged
phospholipid-dependent coagulation time, presented
with significantly higher levels of aCL than the controls
(healthy dogs of other breeds) [14]. Nonetheless, a re-
cent study did not correlate aPL with thrombosis or
immune-mediated hemolytic anemia in dogs [15]. The
involvement of aPL with thrombocytopenia, a clinical
manifestation frequently occurred in APS patients, re-
mains to be clarified in dogs.
We initiated the investigation on dogs with
thrombocytopenia, in particular, immune thrombocytopenia
that usually manifests with significantly lower platelet
counts than thrombocytopenia of other origins [16]. The
objective of this study was to explore whether any subtypes
of aPL are associated with thrombocytopenia or immune
thrombocytopenia in pet dogs. Indirect ELISAs were per-
formed to measure and compare the levels and prevalence
of aPhL, aβ2GPI, aCL, aPI, aPC, and aPS IgG antibodies in
outpatient dogs with or without thrombocytopenia and in
healthy dogs.
Results
Normal platelet reference range of dogs is 200 – 500 ×
103/uL [17]. However, dogs with a platelet count of less
than 80 × 103/uL are more likely to have clinical compli-
cations [17]. In our study, serum samples were divided
into three groups. Group I consisted of 64 outpatient
dogs with thrombocytopenia (platelet count 0 – 80 ×
103/uL). Group II consisted of 30 outpatient dogs with-
out thrombocytopenia (platelet count 250 – 500 × 103/
uL). To avoid any interference from other APS-related
manifestations, dogs with thrombosis, pregnancy mor-
bidity, and hemolytic anemia were not included in
Group I and Group II outpatient dogs. As a control,
Group III consisted of 80 healthy dogs. Group I has an
average age of 5.2 years and a female to male ratio of
1.1. Group II has an average age of 5.9 years and a fe-
male to male ratio of 1.2. Group III has an average age
of 2.8 and a female to male ratio of 0.7. Basic
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information (including breed) of three groups of dogs
and clinical manifestations of outpatient dogs (Group I
and Group II) are listed in the Additional file 1.
In dogs, immune thrombocytopenia often manifests
with significantly lower platelet counts than other
forms of thrombocytopenia [16]. Therefore, a diagnosis
of presumptive immune thrombocytopenia is usually
made if a dog’s platelet count falls below certain cut-off
values [18]. For example, O’Marra et al. [18] have cate-
gorized thrombocytopenic dogs with platelet counts of
less than 30 × 103/μL and without any other underlying
disease as having presumptive primary immune
thrombocytopenia. Furthermore, a recent study by Iraqi
et al. [19] has verified the pathological role of antiplate-
let antibodies (aPLT) in the development of immune
thrombocytopenia. In the present study, we selected 38
outpatient dogs with severe thrombocytopenia (platelet
count < 30 × 103/μL) from Group I and examined their
sera for the presence of aPLT. Positive threshold for
aPLT (1.5 ng/mL) was determined as 99th percentile of
healthy dogs (in the Group III). Group I dogs were fur-
ther divided into three subgroups. Severe thrombocyto-
penic dogs with positive aPLT were designated as Group
IA (categorized as having immune thrombocytopenia) (n
= 20), which included outpatient dogs with primary
immune thrombocytopenia and those with immune
thrombocytopenia secondary to other diseases. Severe
thrombocytopenic dogs negative for aPLT were designated
as Group IB (n = 18). On the other hand, less severe
thrombocytopenic dogs with platelet count between 30 –
80 × 103/μL were designated as Group IC (n = 26). The
average level of aPLT in Group IA was 3.8 ng/mL (ranging
from 1.9 to 15.3 ng/mL). The results of aPLT
measurement in Group IA, Group IB, and healthy control
are shown in the Additional file 2.
Expression of β2GPI antigen for aβ2GPI antibodies
detection
The presence of aβ2GPI antibodies has been listed as
one of the laboratory criteria for the diagnosis of APS
[2]. For the detection of aβ2GPI antibodies in dogs, we
cloned human β2GPI cDNA from HeLa cells and
expressed the recombinant β2GPI (rβ2GPI). The rβ2GPI
protein was purified by metal chelation chromatography.
The purified rβ2GPI protein was analyzed by SDS-PAGE
and Western blot, and the identity of rβ2GPI was veri-
fied by mass spectrometry (Additional file 3).
Dog IgG and human aPhL IgG standard curves
Using commercially quantified dog IgG as standards, we
performed a sandwich ELISA to establish a standard
curve for dog IgG calibration. Rabbit anti-dog IgG
F(ab)2 fragment antibodies were used as capture anti-
bodies, and dog IgG standards (200, 100, 50, 25, 12.5,
6.25, 3.125, and 0 μg/mL) were added as calibrators. A
standard ELISA curve, with an R squared value of
0.9726, was generated by using linear regression (Fig. 1a).
This standard equation was applied to deduce IgG con-
centrations (μg/mL) of various autoantibodies in canine
sera (OD = 0.0109 × concentration + 0.0787).
As a comparison, reference human aPhL IgG stan-
dards (200, 100, 50, 25, 12.5, and 6.25 μg/mL) available
in a human APhL IgG ELISA kit were used. A standard
ELISA curve was generated by using linear regression,
with an R squared value of 0.9961 (Fig. 1b).
Fig. 1 Dog IgG and human aPhL IgG standard curves. A sandwich ELISA was performed to establish a calibration curve for dog IgG (panel a).
Rabbit anti-dog IgG F(ab)2 fragment antibodies were coated onto the ELISA plate. Different concentrations (200 ng/mL, 100 ng/mL, 50 ng/mL,
25 ng/mL, 12.5 ng/mL, 6.25 ng/mL, 3.125 ng/mL) of dog IgG were added into each well. Peroxidase conjugated-rabbit anti-dog IgG Fc fragment
antibody was used to detect dog IgG. OD = 0.0109 × concentration + 0.0787. R2 = 0.9726. To obtain a human aPhL IgG standard curve, aPhL IgG
reference calibrators (200, 100, 50, 25, 12.5, and 6.25 μg/mL) available in a human APhL IgG ELISA kit were used (panel b). OD = 0.0086 ×
concentration + 0.0482. R2 = 0.9961. The OD (450 nm) values are shown as means ± standard error (SE)
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Comparing serum levels of aPL subtypes in different
groups of dogs
By using an indirect ELISA, a mixture of non-cardiolipin
phospholipids (PhL) consisting of PS, phosphatidic acid
(PA), and β2GPI, available from an APhL IgG HRP
ELISA kit, were incubated sequentially with diluted
(1:50) canine sera and with HRP conjugated-rabbit anti-
dog IgG antibodies to measure aPhL in canine sera.
Similarly, using rβ2GPI, CL, PI, PC, and PS as the coated
antigens, we added canine sera (1:50) and HRP
conjugated-rabbit anti-dog IgG antibodies to measure
aβ2GPI, aCL, aPI, aPC, and aPS in canine sera by indir-
ect ELISAs.
The average ELISA OD readings for aPhL, aβ2GPI,
aCL, aPI, aPC, and aPS obtained from outpatient dogs
with thrombocytopenia (Group I), and subgroups IA, IB,
and IC were all significantly higher than those healthy
dogs (Group III) (Fig. 2). Average OD readings for aPhL
and aCL obtained from Group I and subgroups IA, IB,
and IC were significantly higher than those obtained
from Group II (Fig. 2). In addition, compared with
Group II, Group I and subgroup IA had significantly
higher levels of aβ2GPI and aPC whereas subgroup IB
had significantly higher level of aPI.
Based on the equation derived from the standard
ELISA curve (Fig. 1), the OD readings of indirect ELISAs
(Fig. 2) were converted directly into IgG levels (μg/mL
or GPL) for aPhL, aβ2GPI, aCL, aPI, aPC, and aPS
(Table 1). From high to low, average IgG levels of aPhL,
aβ2GPI, aCL, aPI, aPC, and aPS among outpatient dogs
with thrombocytopenia (subgroups IA, IB, and IC) were
95 – 131, 40 – 66, 39 – 60, 17 – 25, 17 –21, and 13 –
18 GPL, respectively (Table 1). On the other hand, aver-
age IgG levels of aPhL, aβ2GPI, aCL, aPI, aPC, and aPS
in outpatient dogs without thrombocytopenia (Group II)
were lower than those of Group I, but higher than those
of Group III (Table 1).
Because the average age of Group III healthy dogs was
lower than the average ages of the outpatient dogs
(Group I and Group II) (Additional file 1), we investi-
gated whether age affected the level of antiphospholipid
antibodies in healthy dogs. Group III (healthy dogs) were
divided into older and younger subgroups. The average
ELISA OD readings for aPhL, aβ2GPI, aCL, aPI, aPC,
and aPS obtained from older and younger subgroups
were not significantly different (Additional file 4). In
addition, considering that the female to male ratio in
Group III healthy dogs was lower than the ratios among
the outpatient dogs (Group I and Group II), we divided
Group III into female and male subgroups to explore
whether gender was a factor for the antiphospholipid
antibodies in healthy dogs. The average ELISA OD
readings for aPhL, aβ2GPI, aCL, aPI, aPC, and aPS were
comparable in the female and male subgroups
Fig. 2 Levels of aPL subtypes determined by ELISA. The aPL subtypes in canine sera were measured. Group I: outpatient dogs with thrombocytopenia
(n = 64). Subgroups of Group I: IA (n = 20) (immune thrombocytopenia, aPLT
+, platelet count < 30 × 103/uL), IB (n = 18) (severe thrombocytopenia,
aPLT-, platelet count < 30 × 103/uL), and IC (n = 26) (less severe thrombocytopenia, platelet count 30 – 80 × 10
3/uL). Group II: outpatient dogs without
thrombocytopenia (n = 30). Group III: healthy dogs (n = 80). *Group I, or subgroup IA, IB, or IC is significantly higher than Group II (
***P < 0.001, **P < 0.01,
*P < 0.05). †Group III is significantly lower than Group I, and subgroups IA, IB, and IC (
†††P < 0.001). The OD (450 nm) values are shown as means ± SE
Chen et al. BMC Veterinary Research  (2016) 12:106 Page 4 of 9
(Additional file 4). The fact that levels of aPhL, aβ2GPI,
aCL, aPI, aPC, and aPS were comparable between older
and younger subgroups, and between female and male
subgroups among healthy dogs excludes the need for
setting any age- or gender-specific positive thresholds.
Frequencies of aPL subtypes based on the 98th or 99th
percentile cut-off values and relative risks for
thrombocytopenia
The positive thresholds for aPL subtypes were determined
either as the average OD values obtained from Group III
healthy dogs plus two standard deviations (SD) (around
98th percentile) or plus 2.33 SD (99th percentile). Based on
the 98th or 99th percentile cut-off values, the frequencies
of positive aPhL, aβ2GPI, aCL, aPI, aPC, and aPS in out-
patient dogs with thrombocytopenia (Group I and sub-
groups IA, IB, and IC) were significantly higher (P < 0.001)
than in healthy dogs (Group III). Comparing between
Group I (or subgroup IA, IB, or IC) and Group III, the rela-
tive risks for outpatient dogs positive for aPhL, aβ2GPI,
aCL, aPI, aPC, aPS versus (vs.) healthy dogs negative
for those aPL subtypes to develop thrombocytopenia
were 73 – ∞, 7 – 30, 67 – ∞, 2 – 10, 3 – 10, and 4 –
19, respectively (Tables 2 and 3).
Among outpatient dogs, the positive frequency of aCL
(98th or 99th percentile cut-off ) was significantly higher
in Group I (98 %) and subgroup IA (95 %), IB (100 %),
and IC (100 %) than in outpatient dogs without
thrombocytopenia (Group II) (Tables 2 and 3). The rela-
tive risks of aCL positive outpatient dogs (vs. aCL nega-
tive outpatient dogs) for having thrombocytopenia
(Group I), immune thrombocytopenia with aPLT (sub-
group IA), severe thrombocytopenia without aPLT (IB),
and less severe thrombocytopenia (IC) were 8.3, 5.3, ∞
(odds ratio 19) and ∞ (odds ratio 27), respectively. In
addition to aCL, significantly higher positive frequencies
of aβ2GPI (85 %), aPC (65 % or 60 %), and aPS (80 %)
were observed in Group IA than those observed in
Group II, with relative risks around 2 (1.9 – 2.9). In
comparison with Group II, the positive frequency of aPS
(83 % or 78 %) was significantly higher in Group IB, with
a relative risk of 3.2 or 2.7 (Tables 2 and 3).
Discussion
In this study, we used indirect ELISAs to measure and
compare serum IgG levels of aPL subtypes (aPhL,
aβ2GPI, aCL, aPI, aPC, and aPS) in dogs with or without
thrombocytopenia and in healthy dogs. Using a
Table 1 Average IgG levels of antiphospholipid antibodies (aPL) among different groups of dogs
aPL subtype IA




(n = 20) (n = 18) (n = 26) (n = 30) (n = 80)
GPLb (95 % CI)c GPL (95 % CI) GPL (95 % CI) GPL (95 % CI) GPL (95 % CI)
aPhL 95.9 (79.3 – 112.5) 116.7 (99.4 – 134.0) 130.9 (105.2 – 156.6) 66.8 (56.5 – 77.0) 7.4 (5.8 – 9.1) 23.1/25.4
aβ2GPI 65.7 (50.6 – 80.7) 40.8 (30.2 – 51.4) 64.9 (44.6 – 85.2) 40.4 (29.0 – 51.8) 6.1 (4.0 – 8.3) 26.7/30.4
aCL 38.8 (28.8 – 48.8) 49.6 (34.3 – 65.0) 58.9 (43.8 – 73.9) 18.3 (11.9 – 24.8) 0.8 (0.2 – 1.3) 5.6/7.1
aPI 18.5 (12.6 – 24.3) 24.4 (19.2 – 29.7) 17.1 (10.8 – 23.4) 15.6 (11.4 – 19.8) 4.2 (2.4 – 5.9) 20.3/23.6
aPC 21.0 (14.5 – 27.4) 17.4 (12.7 – 22.1) 17.5 (12.6 – 22.3) 11.8 (8.4 – 15.2) 3.2 (2 – 4.4) 15.7/17.5
aPS 16.8 (11.0 – 22.5) 18.0 (12.9 – 23.0) 13.5 (8.4 – 18.6) 11.2 (6.3 – 16.2) 0.8 (0.2 – 1.4) 5.6/7.3
aSubgroups of Group I (thrombocytopenia): IA (immune thrombocytopenia, aPLT
+, platelet < 30 × 103/uL), IB (severe thrombocytopenia, aPLT
-, platelet < 30 × 103/uL), and
IC (less severe thrombocytopenia, platelet 30 – 80 × 10
3/uL). bConcentrations (μg/mL of IgG, GPL) were converted directly from the OD readings based on the equation
shown in Fig. 1a. One GPL unit is defined as the binding activity of 1 μg/mL of IgG. c95% confidence interval. dOutpatient dogs without thrombocytopenia (Group II).
eHealthy dogs (Group III)
Table 2 Frequency of antiphospholipid antibodies among different groups of dogs based on the 98th percentile cut-off
aPL subtype I/IA/IB/IC
a IIb IIIc I/IA/IB/IC I/IA/IB/IC
n = 64/20/18/26 n = 30 n = 80 vs. II vs. III
positive (%) positive (%) positive (%) relative risk (odds ratio)d, e relative risk (odds ratio)
aPhL 63/20/18/25 (98/100/100/96) 27 (90) 2 (3) 2.8/(5.2)/(4.7)/1.9 76***/(1287)***/(1162)***/73***
aβ2GPI 52/17/15/20 (81/85/83/77) 16 (53) 3 (4) 1.6**/2.9*/2.7/1.8 7.0***/22***/22***/12***
aCL 63/19/18/26 (98/95/100/100) 20 (67) 3 (4) 8.3***/5.3*/(19)**/(27)*** 74***/67***/(819)***/(1174)***
aPI 30/8/12/10 (47/40/67/38) 7 (23) 4 (5) 1.3*/1.5/2.4*/1.4 2.8***/4.8***/10***/4.1***
aPC 38/13/12/13 (59/65/67/50) 9 (30) 4 (5) 1.4*/2.3*/2.5*/1.5 3.5***/9.0***/10***/5.2***
aPS 50/16/15/19 (78/80/83/73) 14 (47) 5 (6) 1.6**/2.6*/3.2*/1.8 5.7***/15***/19***/9.2***
aSubgroups of Group I (thrombocytopenia): IA (immune thrombocytopenia, aPLT
+, platelet < 30 × 103/uL), IB (severe thrombocytopenia, aPLT
-, platelet < 30 × 103/
uL), and IC (less severe thrombocytopenia, platelet 30 – 80 × 10
3/uL). bGroup II: outpatient dogs without thrombocytopenia. cGroup III: healthy dogs. dOdds ratio is
shown in parenthesis if relative risk is ∞. eValue > 2 is shown in bold. *Frequencies are significantly different (*P < 0.05; **P < 0.01; ***P ≤ 0.001)
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secondary antibody to amplify signal, indirect ELISA is
more sensitive than direct ELISA [20]. In addition, indir-
ect ELISA allows us to use one common conjugated sec-
ondary antibody to measure different aPL subtypes.
At this point, reference dog sera are not available nor
have cut-off values been established for canine aPL sub-
types other than aCL. In an earlier report, Papini et al.
[13] estimated canine aCL levels based on an equation
obtained from measuring human reference sera and de-
termined the cut-off value as mean plus 2 SD. In our
study, we measured levels of aPL subtypes based on a
standard curve established for dog IgG calibration
(Fig. 1a), which appeared comparable to that generated
by using reference human aPhL IgG standards (Fig. 1b).
In humans, ELISA cut-off values for aCL have been di-
versely determined as mean plus 2 SD (around 98th per-
centile) or 3 SD or 5 SD, or at the 95th or 99th
percentiles [21–26]. In our present study, we assessed
and compared the association of aPL subtypes with
thrombocytopenia based on the 98th percentile (mean of
healthy dogs plus 2 SD) and 99th percentile (mean plus
2.33 SD) cut-off values. Based on these cut-off values,
canine sera determined as aPhL positive could compete
with human reference serum (available in the APhL IgG
HRP ELISA kit) for PhL (non-cardiolipin phospholipids)
binding (Additional file 5), indicating that our ELISA is
reliable.
We mainly investigated aPL subtypes on clinically rele-
vant thrombocytopenic outpatient dogs (Group I) that
have much lower platelet count (0 – 80 × 103/uL) than
Group II (250 – 500 × 103/uL). This approach reduces
the chance of overlapping grouping. We further divided
thrombocytopenic dogs into three subgroups to explore
the relevance of aPL subtypes to the severity of the dis-
ease (Group IA/Group IB vs. Group IC) and to the pres-
ence or absence of aPLT (Group IA vs. Group IB).
Frequencies of aPC, and aPS appeared higher in severe
thrombocytopenic dogs (Group IA and Group IB) than
in less severe thrombocytopenic dogs (Group IC)
whereas frequencies of aCL and aβ2GPI were higher
within thrombocytopenic outpatient dogs than in those
without thrombocytopenia (Tables 2 and 3). In contrast,
aPhL frequencies are comparably high among outpatient
dogs (Tables 2 and 3). Interestingly, such tendencies (re-
garding aCL, aβ2GPI, aPC, aPS, aPhL) were also ob-
served when we compared frequencies of aPL subtypes
in mild thrombocytopenic dogs (platelet count 81 –
199 × 103/uL) with those in Group I (platelet count 0 –
80 × 103/uL) thrombocytopenic dogs or those in Group
II (platelet count 250 – 500 × 103/uL) (Additional file 6,
Tables 2 and 3). These results suggest that aCL and
aβ2GPI could have potential to be markers for
thrombocytopenia among outpatients dogs and the pres-
ence of aPC and aPS may help to reflect the severity of
thrombocytopenia.
Among all tested aPL subtypes, aCL poses the high-
est relative risk in outpatient dogs for having
thrombocytopenia (8.3), immune thrombocytopenia with
aPLT (5.3), severe thrombocytopenia without aPLT (∞,
odds ratio 19), or less severe thrombocytopenia (∞, odds
ratio 27) (Tables 2 and 3). This result indicates an import-
ant role of aCL in canine thrombocytopenia, including
immune thrombocytopenia and particularly in severe
thrombocytopenia without aPLT and in less severe
thrombocytopenia. Furthermore, based on higher relative
risks, outpatient dogs present with aβ2GPI (relative risk
2.9 or 1.9) and aPC (relative risk 2.3 or 2.0) are around
two fold more likely to have immune thrombocytopenia
(with aPLT) and those with aPS are two to three fold more
likely to have immune thrombocytopenia (relative risks
2.6 or 2.9) or severe thrombocytopenia without aPLT (3.2
or 2.7) (Tables 2 and 3). In the future, it would be inter-
esting to explore whether aCL, aβ2GPI, aPC, and aPS
poses differential risks under the presence or absence
of aPLT in less severe thrombocytopenia or even mild
thrombocytopenia. It is worth noting that our supple-
ment data indicate that the levels of all the aPL sub-
types examined here were not significantly different
Table 3 Frequency of antiphospholipid antibodies among different groups of dogs based on the 99th percentile cut-off
aPL subtype I/IA/IB/IC
a IIb IIIc I/IA/IB/IC I/IA/IB/IC
n = 64/20/18/26 n = 30 n = 80 vs. II vs. III
positive (%) positive (%) positive (%) relative risk (odds ratio)d, e relative risk (odds ratio)
aPhL 63/20/18/25 (98/100/100/96) 26 (87) 2 (3) 3.5*/(6.9)/(6.2)/2.4 76***/(1287)***/(1162)***/73***
aβ2GPI 49/17/12/20 (77/85/67/77) 16 (53) 2 (3) 1.4*/1.9*/1.4/1.8 30***/24***/12***/12***
aCL 63/19/18/26 (98/95/100/100) 20 (67) 3 (4) 8.3***/5.3*/(19)**/(27)*** 74***/67***/(819)***/(1174)***
aPI 25/8/9/8 (39/40/50/31) 6 (20) 3 (4) 1.3/1.7/2.2/1.3 2.2***/5.3***/7.1***/3.8***
aPC 35/12/11/12 (55/60/61/46) 9 (30) 4 (5) 1.3*/2.0*/2.2/1.4 3.2***/7.8***/8.7***/4.8***
aPS 45/16/14/15 (70/80/78/58) 13 (43) 4 (5) 1.4*/2.9*/2.7*/1.3 4.5***/16***/15***/6.2***
aSubgroups of Group I (thrombocytopenia): IA (immune thrombocytopenia, aPLT
+, platelet < 30 × 103/uL), IB (severe thrombocytopenia, aPLT
-, platelet < 30 × 103/
uL), and IC (less severe thrombocytopenia, platelet 30 – 80 × 10
3/uL). bGroup II: outpatient dogs without thrombocytopenia. cGroup III: healthy dogs. dOdds ratio is
shown in parenthesis if relative risk is ∞. eValue > 2 is shown in bold. *Frequencies are significantly different (*P < 0.05; **P < 0.01; ***P < 0.001)
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between older and younger subgroups of normal
healthy dogs (Additional file 4). This observation is in
agreement with that reported by Budd et al. [26] for
human aCL.
Although the average IgG levels of aPhL were signifi-
cantly higher (P < 0.001) in outpatient dogs with
thrombocytopenia or immune thrombocytopenia than in
those without (Fig. 2), the fact that prevalences of posi-
tive aPhL in thrombocytopenia or immune thrombocy-
topenic outpatient dogs and in outpatient dogs with
other diseases were comparably high indicates that the
presence of aPhL may thus not be applicable as a diag-
nostic criterion for canine thrombocytopenia, immune
thrombocytopenia, or APS-related disorders. Interest-
ingly, aPhL, recognizing a mixture of non-cardiolipin an-
tigens, which are comprised of PS, PA, and β2GPI, have
been reported to be specifically detected in human pa-
tients with antiphospholipid syndrome (APS) and not in
other disorders [6–8]. There could be disparities be-
tween human and canine APS regarding the specificity
of aPL subtypes or clinical manifestations. For example,
the results of our study indicate that aPhL, preferentially
detected in human APS patients, may not be specific for
APS-related disorders in dogs. In particular, canine aPA
that was not examined individually in our present study
(as opposed to two other aPhL subtypes, aPS and
aβ2GPI) deserves future investigation. In addition, a re-
cent study has shown that thrombosis, which is known
to be associated with aPL and is listed as one marked
manifestation for the diagnosis of APS in humans [2,
27], may not be correlated well with aPL in dogs [15].
Overall, here in our study we observed a high preva-
lence of aPL (adding up all aPL subtypes) in outpatient
dogs with thrombocytopenia (98 %, Group I), immune
thrombocytopenia with positive aPLT (100 %, Group
IA), severe thrombocytopenia without aPLT (100 %,
Group IB). Interestingly, in the recently held 14
th Inter-
national Antiphospholipid Congress, experts in the
field discussed whether to include thrombocytopenia
and several other non-criteria clinical manifestations
of APS as APS classification criteria [28]. Based on
data presented in related medical literature and con-
sidering that aPL related thrombocytopenia increases
the risk of thrombosis, Abreu et al. [28] categorize
thrombocytopenia as “recommended to be included as
part of APS criteria revision” although the quality of
data is low. In the future, it is imperative to carry out ex-
tensive investigations to clarify whether thrombocytopenia
can be listed as one clinical manifestation of human
APS or canine APS-related disorders. Follow-up
surveys are needed to compare the incidence of
thrombocytopenia, pregnancy morbidity, hemolytic
anemia, and thrombosis among dogs with positive anti-
phospholipid antibodies.
Conclusions
Of all the aPL subtypes tested here, aCL is highly associ-
ated with canine thrombocytopenia, including immune
thrombocytopenia, and particularly severe thrombocytopenia
negative for aPLT and less severe thrombocytopenia. Fur-
thermore, aPS is moderately associated with both canine
immune thrombocytopenia and severe thrombocytopenia
negative for aPLT, whereas aβ2GPI, and aPC are moder-
ately relevant to canine immune thrombocytopenia. In
contrast, aPI is not significantly associated with canine im-
mune thrombocytopenia.
Methods
Canine blood and platelet count
EDTA-anticoagulated blood samples (for platelet count)
or sera were taken from outpatient dogs admitted to the
Veterinary Medical Teaching Hospital, National Chung
Hsing University (Taichung, Taiwan, ROC) or from
healthy dogs (based on physical examination and/or
platelet count) whose owners had volunteered to bring
their dogs in for a checkup. Platelet counts were mea-
sured using a KX-21 N Hematology Analyzer (Sysmex,
Kobe, Japan). Owner consents were obtained before col-
lecting blood from dogs. Sera were stored at -20 °C.
Detection of canine aPLT by indirect ELISAs
For the detection of aPLT in serum samples, an indirect
ELISA was carried out according to the manual of the
canine PA-IgG/M/A ELISA kit (Novatein Biosciences,
Woburn, MA, USA). Positive threshold for aPLT was
determined as mean plus 2.33 SD (99th percentile cut-off
value) of healthy dogs (Group III of this study). Detailed
method was described in the supporting information
(Additional file 2).
β2GPI expression and identification
Methods for the cDNA cloning, recombinant protein ex-
pression and identification of human β2GPI were de-
scribed in the supporting information (Additional file 3).
ELISA for dog IgG calibration
Fifty μL per well of 50 ng/mL rabbit anti-dog IgG-F(ab)2
fragment antibodies (Bethyl Laboratories, Montgomery,
TX, USA) in ELISA coating buffer (15 mM NaCO3,
35 mM NaHCO3 at pH 9.6) were added into a 96-well
plate and incubated overnight at 4 °C. The next day,
each well was fixed with 100 μL of methanol for 10 min
and washed twice with phosphate-buffered saline (PBS).
The plate was air-dried. Each well was incubated with
100 μL of blocking buffer for 60 min. After removing
the blocking buffer, 100 μL of serial 2-fold dilutions (in
PBS) of dog IgG (Sigma, St. Louis, MO, USA) were
added into each well and incubated for 30 min at 37 °C.
After washing three times (15 min for each wash) with
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200 μL of PBS, 100 μL of horseradish peroxidase (HRP)-
conjugated rabbit anti-dog IgG Fc fragment specific anti-
bodies (Jackson ImmunoResearch, West Grove, PA,
USA) (1:10000 in blocking buffer, PBS containing 3 %
normal rabbit serum) were added to each well and incu-
bated for 30 min at 37 °C. After three washes, 100 μL of
3,3’,5,5’-tetramethylbenzidine (TMB) solution was added
and incubated for 30 min in the dark. Finally, 100 μL of
1 M H2SO4 was added to stop the reaction. The optical
density (OD) was measured at 450 nm by using a μquant
ELISA reader (BioTek, Winooski, VT, USA). Each of the
concentrations above were repeated in triplicate to es-
tablish a standard ELISA curve.
An indirect ELISA for human IgG aPhL standards
Using APhL IgG calibrators (provided in the kit) con-
taining quantified reference human aPhL IgG, an indir-
ect ELISA was performed according to the manual of
the APhL IgG HRP ELISA kit (Louisville APL Diagnos-
tics, Doraville, GA, USA). Briefly, each of the 96 wells
was incubated for 30 min with 100 μL of pre-diluted ref-
erence human sera. After three washes, HRP conjugated
anti-human IgG antibodies provided in the kit was
added into each well and incubated for 30 min. Sub-
strate solution was added and incubated for 30 min in
the dark. Finally, 100 μL of stop solution was added to
stop the reaction. The optical density (OD) was mea-
sured at 450 nm by using a μquant ELISA reader
(BioTek).
Detection of canine aPhL, aCL, aPI, aPC, aPS, and aβ2GPI
IgG by indirect ELISAs
The coated phospholipid antigens in an APhL IgG HRP
ELISA kit (Louisville APL Diagnostics) were used as an-
tigens to detect aPhL in canine sera. For aCL, aPI, aPC,
and aPS detections, 30 μL (50 μg/mL in ethanol) of car-
diolipin (CL), phosphatidylinositol (PI), phosphatidyl-
choline (PC), and PS (Sigma) were coated onto each of
the 96 wells by evaporation. For the detection of
aβ2GPI IgG antibodies, 50 μL of rβ2GPI (1 μg/mL in
ELISA coating buffer) were added into each of the 96
wells. The plate was coated and fixed with methanol.
The following procedures were the same as described
above for the dog IgG sandwich ELISA, except that
100 μL of diluted canine serum (1:50 in blocking buf-
fer) were added instead of adding serial 2-fold dilutions
of dog IgG.
Sequence accession number
The sequence of human β2GPI cDNA isolated in this
study was deposited in GenBank under accession num-
ber HM212425.
Statistical analysis
Chi-square (χ2) analysis, two-sided Fisher’s exact test
(for small expected frequencies), and t-test were
employed, and relative risks or odds ratios were calcu-
lated to correlate aPhL, aβ2GPI, aCL, aPI, aPC, and aPS
IgG antibodies with thrombocytopenia or immune
thrombocytopenia by using Prism statistical software
(version 6.0, GraphPad Software, La Jolla, CA).
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